BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Brown EG, Goldman SM. Modulation of the Microbiome in Parkinson's Disease: Diet, Drug, Stool Transplant, and Beyond. Neurotherapeutics 2020;17:1406-17. [PMID: 33034846 DOI: 10.1007/s13311-020-00942-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
Number Citing Articles
1 Arena G, Sharma K, Agyeah G, Krüger R, Grünewald A, Fitzgerald JC. Neurodegeneration and Neuroinflammation in Parkinson's Disease: a Self-Sustained Loop. Curr Neurol Neurosci Rep 2022. [PMID: 35674870 DOI: 10.1007/s11910-022-01207-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Fu T, Shen L. Ergothioneine as a Natural Antioxidant Against Oxidative Stress-Related Diseases. Front Pharmacol 2022;13:850813. [DOI: 10.3389/fphar.2022.850813] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Safarpour D, Sharzehi K, Pfeiffer RF. Gastrointestinal Dysfunction in Parkinson’s Disease. Drugs. [DOI: 10.1007/s40265-021-01664-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
4 Bicknell B, Liebert A, McLachlan CS, Kiat H. Microbiome Changes in Humans with Parkinson's Disease after Photobiomodulation Therapy: A Retrospective Study. J Pers Med 2022;12:49. [PMID: 35055364 DOI: 10.3390/jpm12010049] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
5 Vijiaratnam N, Simuni T, Bandmann O, Morris HR, Foltynie T. Progress towards therapies for disease modification in Parkinson's disease. Lancet Neurol 2021;20:559-72. [PMID: 34146514 DOI: 10.1016/S1474-4422(21)00061-2] [Cited by in F6Publishing: 21] [Reference Citation Analysis]
6 Dudás EF, Huynen MA, Lesk AM, Pastore A. Invisible leashes: The tethering VAPs from infectious diseases to neurodegeneration. J Biol Chem 2021;296:100421. [PMID: 33609524 DOI: 10.1016/j.jbc.2021.100421] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
7 Tanner CM, Ostrem JL. Therapeutic Advances in Movement Disorders. Neurotherapeutics 2020;17:1325-30. [PMID: 33452629 DOI: 10.1007/s13311-020-00988-2] [Reference Citation Analysis]